HUP0301161A3 - Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleate and process for their preparation - Google Patents

Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleate and process for their preparation

Info

Publication number
HUP0301161A3
HUP0301161A3 HU0301161A HUP0301161A HUP0301161A3 HU P0301161 A3 HUP0301161 A3 HU P0301161A3 HU 0301161 A HU0301161 A HU 0301161A HU P0301161 A HUP0301161 A HU P0301161A HU P0301161 A3 HUP0301161 A3 HU P0301161A3
Authority
HU
Hungary
Prior art keywords
thiazolidine
pyridyl
ethoxy
benzyl
amino
Prior art date
Application number
HU0301161A
Other languages
Hungarian (hu)
Original Assignee
Reddy S Res Foundation Hyderab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy S Res Foundation Hyderab filed Critical Reddy S Res Foundation Hyderab
Publication of HUP0301161A2 publication Critical patent/HUP0301161A2/en
Publication of HUP0301161A3 publication Critical patent/HUP0301161A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
HU0301161A 2000-09-26 2001-09-25 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleate and process for their preparation HUP0301161A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN805CH2000 2000-09-26
PCT/US2001/029896 WO2002026737A1 (en) 2000-09-26 2001-09-25 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation

Publications (2)

Publication Number Publication Date
HUP0301161A2 HUP0301161A2 (en) 2003-11-28
HUP0301161A3 true HUP0301161A3 (en) 2005-04-28

Family

ID=29266775

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301161A HUP0301161A3 (en) 2000-09-26 2001-09-25 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleate and process for their preparation

Country Status (15)

Country Link
EP (1) EP1322647A1 (en)
JP (1) JP2004509961A (en)
AU (1) AU9123201A (en)
BR (1) BR0114196A (en)
CA (1) CA2426117A1 (en)
CZ (1) CZ2003864A3 (en)
HU (1) HUP0301161A3 (en)
IL (1) IL155036A0 (en)
MX (1) MXPA03002580A (en)
NO (1) NO324968B1 (en)
NZ (1) NZ525498A (en)
PL (1) PL360661A1 (en)
SK (1) SK3752003A3 (en)
WO (1) WO2002026737A1 (en)
ZA (1) ZA200303223B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1173434B1 (en) 1999-04-23 2003-08-20 SmithKline Beecham plc Thiazolidinedione derivative and its use as antidiabetic
PE20010044A1 (en) 1999-04-23 2001-03-10 Smithkline Beecham Plc SALT POLYMORPH OF MALEIC ACID OF 5- [4- [2- (N-METHYL-N- (2-PYRIDYL) AMINO) ETHOXY] BENZYL] -THAZOLIDINE-2,4-DIONA
WO2004062667A1 (en) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
AR047541A1 (en) * 2004-02-13 2006-01-25 Sandoz Ag PHOSPHATE OF 5 - [[4- [2-METHYL-2-PYRIDINYL-AMINO-ETOXI] PHENYL] METHYL] -2,4 THYZOLIDINADION (ROSIGLITAZONE) AND ITS POLYMORPHIC FORMS
WO2005095390A2 (en) * 2004-03-31 2005-10-13 Sandoz Ag Novel co-precipitate of amorphous rosiglitazone
CN1956981A (en) * 2004-05-11 2007-05-02 参天制药株式会社 Agent for treating keratoconjunctival trouble
JP2005350451A (en) * 2004-05-11 2005-12-22 Santen Pharmaceut Co Ltd Agent for treating keratoconjunctival trouble
CZ296472B6 (en) * 2004-07-27 2006-03-15 Zentiva, A. S Salt of oxalic acid with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, process for its preparation and its use
ITMI20041537A1 (en) * 2004-07-28 2004-10-28 Chemi Spa NEW POLYMORPHIC SHAPE OF EVIL ROSIGLITAZONE
CZ298424B6 (en) * 2005-05-24 2007-09-26 Zentiva, A. S. Crystallization process of rosiglitazone and derivatives thereof from mixed solutions
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
CN1196730A (en) * 1996-06-19 1998-10-21 雷迪博士研究基金会 Novel polymorphic forms of troglitazone having enhanced anti-brabetic activity and process for their preparation
EP0923580A1 (en) * 1996-07-26 1999-06-23 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
PE20010044A1 (en) * 1999-04-23 2001-03-10 Smithkline Beecham Plc SALT POLYMORPH OF MALEIC ACID OF 5- [4- [2- (N-METHYL-N- (2-PYRIDYL) AMINO) ETHOXY] BENZYL] -THAZOLIDINE-2,4-DIONA
EP1173434B1 (en) * 1999-04-23 2003-08-20 SmithKline Beecham plc Thiazolidinedione derivative and its use as antidiabetic

Also Published As

Publication number Publication date
MXPA03002580A (en) 2003-10-15
SK3752003A3 (en) 2005-03-04
NO324968B1 (en) 2008-01-14
NZ525498A (en) 2004-11-26
ZA200303223B (en) 2004-07-26
WO2002026737A1 (en) 2002-04-04
AU9123201A (en) 2002-04-08
CA2426117A1 (en) 2002-04-04
EP1322647A1 (en) 2003-07-02
NO20031356L (en) 2003-05-26
WO2002026737A8 (en) 2003-11-06
CZ2003864A3 (en) 2004-01-14
BR0114196A (en) 2003-07-22
NO20031356D0 (en) 2003-03-25
JP2004509961A (en) 2004-04-02
IL155036A0 (en) 2003-10-31
HUP0301161A2 (en) 2003-11-28
PL360661A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
HUP0301161A3 (en) Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleate and process for their preparation
DZ3316A1 (en) Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
HK1045153A1 (en) Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
HUP0100509A3 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical, process for its preparation and its pharmaceutical use
IL136381A (en) Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino) ethoxy] benzyl] thiazolidine-2,4-dione maleic acid salt, its preparation and pharmaceutical compositions comprising it
IL154724A0 (en) The hydrochloride salt of 5-[4- [2- (n-methyl-n- (2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2, 4-dione
IL188116A0 (en) Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione
AP1814A (en) Tartrate salts of thiazolidinedione derivative.
AU6255001A (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical
SI1265893T1 (en) Hydrochloride salts of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione
SI1173435T1 (en) Polymorph of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione maleic acid salt

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees
FD9A Lapse of provisional protection due to non-payment of fees